Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Current Urology
|
January 24, 2022
Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
Hossain Roshani, Erik P M Roos, Henk W Elzevier, et al.
World Journal of Urology
|
June 24, 2016
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
BJU International
|
January 8, 2015
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
BJU International
|
October 19, 2017
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, et al.
Springerplus
|
June 23, 2016
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis
Siebren Dijkstra, Wim P J Witjes, Erik P M Roos, et al.
Journal of Clinical Medicine
|
October 16, 2024
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1
Herjan J T Coelingh Bennink, Erik P M Roos, R Jeroen A van Moorselaar, et al.
Endocrine Connections
|
October 25, 2022
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
Herjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, et al.
European Urology Open Science
|
November 10, 2022
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
Yvette Zimmerman, Mark Frydenberg, Hendrik van Poppel, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
European Urology Open Science
|
August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Current Urology
|
January 24, 2022
Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
Hossain Roshani, Erik P M Roos, Henk W Elzevier, et al.
World Journal of Urology
|
June 24, 2016
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
BJU International
|
January 8, 2015
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, et al.
BJU International
|
October 19, 2017
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)
Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, et al.
Springerplus
|
June 23, 2016
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis
Siebren Dijkstra, Wim P J Witjes, Erik P M Roos, et al.
Journal of Clinical Medicine
|
October 16, 2024
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1
Herjan J T Coelingh Bennink, Erik P M Roos, R Jeroen A van Moorselaar, et al.
Endocrine Connections
|
October 25, 2022
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review
Herjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, et al.
European Urology Open Science
|
November 10, 2022
Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study
Yvette Zimmerman, Mark Frydenberg, Hendrik van Poppel, et al.
The Journal of Urology
|
December 5, 2025
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, et al.
European Urology Open Science
|
August 2, 2021
Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
Herjan J T Coelingh Bennink, Jeroen A van Moorselaar, E David Crawford, et al.
Page
of 1